



## ASX Announcement

### Race secures fourth US patent for bisantrene

---

**22 July 2020** – Race Oncology Limited (“Race” or “the Company”) (ASX: RAC) is pleased to announce that it has secured a new patent on its cancer drug, bisantrene, from the United States Patent and Trademarks Office (USPTO).

This is Race’s fourth patent granted on bisantrene in the United States. “The new US patent allows additional claims around the use of bisantrene that improve the therapeutic benefit of bisantrene and related chemical structures”, said Race’s CSO Dr Daniel Tillett.

The new patent addresses the expanded therapeutic utility of bisantrene (and related chemical structures), in particular, methods and compositions for improving the therapeutic efficacy of bisantrene and reducing side effects.

The new patent (US 10,548,876) builds on Race’s bisantrene patents granted in the USA in 2018 and 2019 (US 9,993,460, US 9,974,774, and US 10,500,192) and further strengthens Race’s IP position for bisantrene.

- ENDS -

#### About Race Oncology (RAC: ASX)

Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called bisantrene. RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting ‘5-Path’ clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020.

Release authorised by:

Daniel Tillett, Chief Scientific Officer & Director

daniel.tillett@raceoncology.com

Media contact:

Jane Lowe, IR Department

+ 61 411 117 774

jane.lowe@irdepartment.com.au

For personal use only